Solid Tumor Clinical Trials in New York, New York

33 studies are recruiting for solid tumor in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

    The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07638371 on ClinicalTrials.gov

  2. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    22 in total
    Run by
    Astellas Pharma Inc

    See if you can join NCT07094204 on ClinicalTrials.gov

  3. Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

    The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the stud…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    10 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04165772 on ClinicalTrials.gov

  4. A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

    The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the acti…

    Stage
    Phase 2
    Ages
    1 and older
    Site
    Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York
    Locations
    16 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05985161 on ClinicalTrials.gov

  5. DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

    The purpose of this study is to improve ways of providing mental health support to Spanish-speaking Latino participants who have cancer and experience depression, insomnia, and fatigue. Investigators will test a special mental health intervention called DESCANSO/REST (Depresión/Depressed Mood, Cans…

    Stage
    Not phased
    Ages
    21 to 100
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    8 in total
    Run by
    Ponce Medical School Foundation, Inc.

    See if you can join NCT07225088 on ClinicalTrials.gov

  6. STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

    This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in advanced unresectable or metastatic tumors. The Phase 2…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    14 in total
    Run by
    STORM Therapeutics LTD

    See if you can join NCT06975293 on ClinicalTrials.gov

  7. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Locations
    15 in total
    Run by
    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

  8. Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

    This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn …

    Stage
    Not phased
    Ages
    Any age
    Site
    Mount Sinai Hospital, New York, New York
    Locations
    164 in total
    Run by
    Children's Oncology Group

    See if you can join NCT00736749 on ClinicalTrials.gov

  9. A Study of ASP3082 in Adults With Advanced Solid Tumors

    This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    68 in total
    Run by
    Astellas Pharma Inc

    See if you can join NCT05382559 on ClinicalTrials.gov

  10. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York
    Locations
    49 in total
    Run by
    Institut de Recherches Internationales Servier

    See if you can join NCT05786924 on ClinicalTrials.gov

  11. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

  12. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Exelixis Clinical Site #60, New York, New York
    Locations
    122 in total
    Run by
    Exelixis

    See if you can join NCT05176483 on ClinicalTrials.gov

  13. Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

    The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05390827 on ClinicalTrials.gov

  14. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

    This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Icahn School of Medicine At Mount Sinai, New York, New York
    Locations
    28 in total
    Run by
    BeOne Medicines

    See if you can join NCT05981703 on ClinicalTrials.gov

  15. A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

    This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Site-117, New York, New York
    Locations
    17 in total
    Run by
    Biohaven Therapeutics Ltd.

    See if you can join NCT06384807 on ClinicalTrials.gov

  16. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    David H Koch, Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    25 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT05245500 on ClinicalTrials.gov

  17. Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

    GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York
    Locations
    11 in total
    Run by
    Georgiamune Inc

    See if you can join NCT06425926 on ClinicalTrials.gov

  18. A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

    Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participan…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05859074 on ClinicalTrials.gov

  19. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

    Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesench…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Medical Center, New York, New York
    Locations
    41 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT04939610 on ClinicalTrials.gov

  20. Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

    This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary an…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    CBCC Global Research Site 010, New York, New York
    Locations
    9 in total
    Run by
    Alyssum Therapeutics

    See if you can join NCT06234098 on ClinicalTrials.gov

  21. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back …

    Stage
    Phase 1
    Ages
    0 to 17
    Site
    Call for Information (Investigational Site 0031), New York, New York
    Locations
    16 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT02332668 on ClinicalTrials.gov

  22. Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

    The purpose of this study is to translate and tailor for Latinx participants a program called Communicating with Oncology Nurses about Values from the Outset (CONVO). In CONVO, routine cancer care for each participant includes a discussion between the nurse and participant about the participant's h…

    Stage
    Not phased
    Ages
    21 and older
    Site
    MSK at Ralph Lauren (All Protocol Activities), New York, New York
    Locations
    5 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04942717 on ClinicalTrials.gov

  23. A Study of PYX-201 in Advanced Solid Tumors

    The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    29 in total
    Run by
    Pyxis Oncology, Inc

    See if you can join NCT05720117 on ClinicalTrials.gov

  24. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

    This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Exelixis Clinical Site #7, New York, New York
    Locations
    11 in total
    Run by
    Exelixis

    See if you can join NCT06952010 on ClinicalTrials.gov

  25. A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

    This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Medical Center- Site Number : 8400013, New York, New York
    Locations
    22 in total
    Run by
    Sanofi

    See if you can join NCT05584670 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.